DelNS1-2019-nCoV-RBD-OPT

DelNS1-2019-nCoV-RBD-OPT
Vaccine description
Target	SARS-CoV-2
Vaccine type	Viral vector
Clinical data
Trade names	Pneucolin
Other names	DelNS1-nCoV-RBD LAIV
Routes of; administration	Intranasal
Identifiers
CAS Number	2696350–29-3;

DelNS1-2019-nCoV-RBD-OPT is a COVID-19 vaccine developed by Beijing Wantai Biological, Xiamen University and the University of Hong Kong.^[3]^[4]^[5] It is administered as a single dose intranasal spray.^[6]

On 14 December 2022, the vaccine was listed by the National Health Commission of China as a secondary booster dose option for people who have completed their third doses of inactivated COVID-19 vaccines for 6 months or longer.^[7]

References

^ "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.
^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
^ "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.
^ "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.
^ "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.
^ Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, et al. (January 2024). "Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study". eClinicalMedicine. 67: 102374. doi:10.1016/j.eclinm.2023.102374. PMC 10758709. PMID 38169940.
^ "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" [Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination] (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.

Scholia has a profile for DelNS1-2019-nCoV-RBD-OPT (Q106522065).

This article about COVID-19 vaccines is a stub. You can help Wikipedia by expanding it.

This article about vaccines or vaccination is a stub. You can help Wikipedia by expanding it.

[1] "A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19". clinicaltrials.gov. United States National Library of Medicine. 29 April 2021. Retrieved 3 May 2021.

[2] "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).

[3] "China's nasal-spray COVID-19 vaccines undergoing clinical trials: official". Xinhua. 11 June 2021. Retrieved 10 July 2021.

[4] "A Phase I Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 7 April 2021. Retrieved 24 March 2021.

[5] "A Phase II Clinical Trial of Influenza virus Vector COVID-19 Vaccine for intranasal Spray (DelNS1-2019-nCoV-RBD-OPT1)". chictr.org.cn. Chinese Clinical Trial Registry. Archived from the original on 14 November 2020. Retrieved 24 March 2021.

[Mi_2023-6] Mi H, Chen Q, Lin H, He T, Zhang R, Ren S, et al. (January 2024). "Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study". eClinicalMedicine. 67: 102374. doi:10.1016/j.eclinm.2023.102374. PMC 10758709. PMID 38169940.

[4th_dose-7] "关于印发新冠病毒疫苗第二剂次加强免疫接种实施方案的通知" [Notice on the implementation plan for the second dose of new coronavirus vaccine booster vaccination] (in Chinese). National Health Commission. 14 December 2022. Retrieved 14 December 2022.

[1]

[2]

[3]

[4]

[5]

[6]

[7]